Search results for "non-alcoholic"

showing 10 items of 271 documents

Gut-adipose tissue axis in hepatic fat accumulation in humans

2014

Recent evidence suggests that in animals gut microbiota composition (GMC) affects the onset and progression of hepatic fat accumulation. The aim of this study was to investigate in humans whether subjects with high hepatic fat content (HHFC) differ in their GMC from those with low hepatic fat content (LHFC), and whether these differences are associated with body composition, biomarkers and abdominal adipose tissue inflammation.Hepatic fat content (HFC) was measured using proton magnetic resonance spectroscopy ((1)H MRS). Fecal GMC was profiled by 16S rRNA fluorescence in situ hybridization and flow cytometry. Adipose tissue gene expression was analyzed using Affymetrix microarrays and quant…

AdultMalemedicine.medical_specialtyPathologyeducationGene ExpressionAdipose tissueFaecalibacterium prausnitziiInflammationGut florata3111Insulin resistanceNon-alcoholic Fatty Liver DiseaseInternal medicineGene expressionmedicineHumansTriglyceridesInflammationHepatologybiologymedicine.diagnostic_testMicrobiotata1183ta1182ta3141Middle Agedta3121biology.organism_classificationmedicine.diseaseCross-Sectional StudiesEndocrinologyReal-time polymerase chain reactionAdipose TissueLiverBody CompositionFemaleInsulin Resistancemedicine.symptomDigestive SystemFluorescence in situ hybridizationJournal of Hepatology
researchProduct

Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program

2019

BACKGROUND Lifestyle modifications remain the cornerstone of treatment in non-alcoholic fatty liver disease (NAFLD). However, they requently fail related to the inability of patients to implement lasting changes. AIMS To evaluate the effects of a short, web-based, individualised exercise program on non-invasive markers of hepatic steatosis, inflammation and fibrosis. METHODS Patients with histologically confirmed NAFLD underwent an 8-week, web-based, individualised exercise program that contained bidirectional feedback. RESULTS Forty-four patients entered the study and 41 completed the assigned training goal (93.2%). In the completer population, 8 weeks of individualised exercise increased …

AdultMalemedicine.medical_specialtyPopulationGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineMedicineHumansPharmacology (medical)030212 general & internal medicineYoung adultExercise physiologyPrecision MedicineeducationExerciseLife Styleeducation.field_of_studyInternetHepatologybusiness.industryFatty liverGastroenterologyMiddle Agedmedicine.disease3. Good healthExercise TherapyQuality of LifeElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleSteatosisbusinessHepatic fibrosisTransient elastographyBiomarkersAlimentary Pharmacology & Therapeutics
researchProduct

Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease.

2014

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is associated with increased cardiometabolic risk. Although dyslipidemia represents a key factor in this disease, its impact on serum levels of distinct lipoprotein subfractions is largely unknown.OBJECTIVE: To assess the full low-density lipoprotein (LDL) and high-density lipoprotein (I-EDL) profiles in patients with NAFLD.METHODS: Seven LDL and 10 HDL subfractions were assessed by gel electrophoresis (Lipoprint, Quantimetrix Corporation, USA) in men with biopsy proven NAFLD (simple steatosis [n = 17, age, 34 7 years] and nonalcoholic steatohepatitis [NASH; n = 24, age, 32 +/- 6 years]). Exclusion criteria included robust alcohol consump…

AdultMalemedicine.medical_specialtySimple steatosiEndocrinology Diabetes and MetabolismBody Mass Indexchemistry.chemical_compoundHigh-density lipoproteinInsulin resistanceNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineNonalcoholic fatty liver diseasemedicineInternal MedicineNutrition and DieteticNonalcoholic fatty liver diseaseHumansAspartate AminotransferasesLipoproteinNutrition and Dieteticsbiologybusiness.industryRisk FactorMedicine (all)Fatty livernutritional and metabolic diseasesAspartate AminotransferaseAlanine TransaminaseLipidMiddle Agedmedicine.diseaseAtherosclerosisFatty LiverLipoproteins LDLEndocrinologyAlanine transaminasechemistryAtherosclerosibiology.proteinFemaleNonalcoholic steatohepatitibusinessCardiology and Cardiovascular MedicineLipoproteins HDLBody mass indexDyslipidemiaLipoproteinHumanJournal of clinical lipidology
researchProduct

Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population

2020

BACKGROUND AND AIMS Non-alcoholic fatty liver (NAFLD) is a major cause of liver disease worldwide leading also to a higher risk of cardiovascular events. We aimed to evaluate the impact of fatty liver and fibrosis on cardiovascular risk in a general population. METHODS Five hundred and forty-two subjects included in the community-based ABCD (Alimentazione, Benessere Cardiovascolare e Diabete) study were recruited. Steatosis (controlled attenuation parameter > 288 dB/m) and severe fibrosis (low risk, liver stiffness measurement [LSM] < 7.9 KPa with M probe and < 5.7 KPa with XL probe; intermediate risk, LSM 7.9-9.5 KPa with M probe and 5.7-9.2 KPa with XL probe; high risk, LSM ≥ 9.6 KPa with…

Adultcardiovascular riskmedicine.medical_specialtyPopulationGastroenterologyAsymptomatic03 medical and health sciencesLiver disease0302 clinical medicineatherosclerosiNon-alcoholic Fatty Liver DiseaseFibrosisInternal medicineNAFLDmedicineHumansSettore MED/49 - Scienze Tecniche Dietetiche Applicateeducationeducation.field_of_studySettore MED/12 - GastroenterologiaHepatologybusiness.industryFatty liverConfoundingGastroenterologyOdds ratiomedicine.diseasecarotidCardiovascular DiseasesHeart Disease Risk Factors030220 oncology & carcinogenesisABCD studyfatty liver disease030211 gastroenterology & hepatologySteatosismedicine.symptombusiness
researchProduct

Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of…

2019

ObjectiveTo systematically review the effect of oral intake of bacterial probiotics on 15 variables related to obesity, diabetes and non-alcoholic fatty liver disease.DesignSystematic review and meta-analysis.Data sourcesMedline, EMBASE and COCHRANE from 1990 to June 2018.Eligibility criteriaRandomised controlled trials (≥14 days) excluding hypercholesterolaemia, alcoholic liver disease, polycystic ovary syndrome and children &lt;3 years.ResultsOne hundred and five articles met inclusion criteria, representing 6826 subjects. In overweight but not obese subjects, probiotics induced improvements in: body weight (k=25 trials, d=−0.94 kg mean difference, 95% CI −1.17 to −0.70, I²=0.0%), body ma…

Alcoholic liver diseasemedicine.medical_specialtyobesitybifidobacteriumGastroenterology03 medical and health sciences0302 clinical medicineInsulin resistanceDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumans030212 general & internal medicine1506BifidobacteriumRandomized Controlled Trials as Topic2. Zero hunger[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismNutrition and Metabolismbiologydiabetesbusiness.industryProbioticsResearchFatty livernon-alcoholic fatty liver diseaseGeneral Medicine[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismmedicine.diseasebiology.organism_classificationPolycystic ovaryObesity3. Good healthlactobacillus[SDV.AEN] Life Sciences [q-bio]/Food and NutritionTreatment Outcome[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieDietary Supplements[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie1714businessBody mass index[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition030217 neurology & neurosurgeryBMJ open
researchProduct

The role of morbid obesity in the promotion of metabolic disruptions and non-alcoholic steatohepatitis by Helicobacter Pylori

2016

Background Helicobacter pylory (HP) infection has been associated to an increased rate of type 2 diabetes (T2D) and liver disease through its effect on insulin resistance and systemic inflammation. However, results are inconstant and no studies exist in morbidly obese patients, in which both insulin resistance and inflammation coexist. Material and methods Cross-sectional study to evaluate the relationship between HP infection and alterations in carbohydrate metabolism, lipid profile, inflammation markers, and liver disease in patients awaiting for bariatric surgery. HP infection was histologically assessed in gastric antrum biopsy from 416 subjects. Liver biopsy was also available in 93 su…

Blood GlucoseMalePhysiologyBiopsylcsh:MedicineType 2 diabetesPathology and Laboratory MedicineBiochemistryGastroenterologyLiver diseaseEndocrinology0302 clinical medicineNon-alcoholic Fatty Liver DiseaseMedicine and Health Sciences030212 general & internal medicinelcsh:ScienceImmune ResponseMultidisciplinarymedicine.diagnostic_testLiver DiseasesFatty liverMiddle AgedObesity MorbidPhysiological ParametersLiver biopsyCarbohydrate MetabolismFemale030211 gastroenterology & hepatologyResearch ArticleAdultmedicine.medical_specialtyEndocrine DisordersImmunologySurgical and Invasive Medical ProceduresGastroenterology and HepatologyHelicobacter Infections03 medical and health sciencesSigns and SymptomsInsulin resistanceDiagnostic MedicineInternal medicineDiabetes mellitusDiabetes MellitusmedicineHumansObesityInflammationHelicobacter pyloriEndocrine Physiologybusiness.industryBody Weightlcsh:RBiology and Life Sciencesmedicine.diseaseImpaired fasting glucoseMorbid ObesityFatty LiverCross-Sectional StudiesMetabolismEndocrinologyDiabetes Mellitus Type 2Metabolic Disorderslcsh:QInsulin ResistanceSteatohepatitisbusiness
researchProduct

Quercetin ameliorates dysregulation of lipid metabolism genes via the PI3K/AKT pathway in a diet-induced mouse model of nonalcoholic fatty liver dise…

2015

Scope Flavonoids and related compounds seem to have favorable effects on nonalcoholic fatty liver disease (NAFLD) progression, although the exact mechanisms implicated are poorly understood. In this study, we aimed to investigate the effect of the flanovol quercetin on gene expression deregulation involved in the development of NAFLD, as well as the possible implication of phosphatidylinositol 3-kinase (PI3K)/AKT pathway modulation. Methods and results We used an in vivo model based on methionine- and choline-deficient (MCD) diet-fed mice and an in vitro model consisting of Huh7 cells incubated with MCD medium. MCD-fed mice showed classical pathophysiological characteristics of nonalcoholic…

CD36 AntigensMalemedicine.medical_specialtyOxidative phosphorylationBiologyMicePhosphatidylinositol 3-Kinaseschemistry.chemical_compoundNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseaseGene expressionmedicineTranscriptional regulationAnimalsLY294002PhosphatidylinositolCells CulturedPI3K/AKT/mTOR pathwayLipid metabolismLipid Metabolismmedicine.diseaseMice Inbred C57BLDisease Models AnimalOxidative StressEndocrinologyGene Expression RegulationchemistryCancer researchQuercetinLipid PeroxidationProto-Oncogene Proteins c-aktSignal TransductionFood ScienceBiotechnologyMolecular Nutrition &amp; Food Research
researchProduct

SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease

2022

Non-alcoholic fatty liver disease (NAFLD), the most frequent liver disease in the Western world, is a common hepatic manifestation of metabolic syndrome (MetS). A specific cure has not yet been identified, and its treatment is currently based on risk factor therapy. Given that the initial accumulation of triglycerides in the liver parenchyma, in the presence of inflammatory processes, mitochondrial dysfunction, lipotoxicity, glucotoxicity, and oxidative stress, can evolve into non-alcoholic steatohepatitis (NASH). The main goal is to identify the factors contributing to this evolution because, once established, untreated NASH can progress through fibrosis to cirrhosis and, ultimately, be co…

Carcinoma HepatocellularSettore MED/09 - Medicina Internatype 2 diabetes mellituSGLT2metabolic syndromeCatalysisInorganic ChemistryNon-alcoholic Fatty Liver DiseaseNAFLDAnimalsHumansHypoglycemic AgentsPhysical and Theoretical ChemistrySodium-Glucose Transporter 2 InhibitorsMolecular BiologySpectroscopyDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentLiver NeoplasmsOrganic Chemistrynutritional and metabolic diseasesGeneral Medicinedigestive system diseasesComputer Science ApplicationsGlucoseLiverDiabetes Mellitus Type 2HumanInternational Journal of Molecular Sciences
researchProduct

Epicardial Fat, Cardiac Geometry and Cardiac Function in Patients with Nonalcoholic Fatty Liver Disease: Association with the Severity of Liver Disea…

2015

Background & Aims Non-alcoholic fatty liver disease (NAFLD) has been associated with increased cardiovascular risk, including coronary artery disease and cardiac dysfunction. In addition, recent evidence highlighted the possible role of epicardial fat as a new cardiometabolic risk factor. We tested the correlation between epicardial fat, alterations in cardiac geometry and function, and severity of liver damage, in patients with biopsy-proven NAFLD. Methods The anthropometric, biochemical and metabolic features were recorded in 147 consecutive biopsy-proven NAFLD cases (Kleiner score). Epicardial fat thickness was measured by echocardiography. Results Epicardial fat was higher in patients w…

Cardiac function curveAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaStatistics as TopicDiastoleEPICARDIAL FATSettore MED/08 - Anatomia PatologicaSeverity of Illness IndexCoronary artery diseaseLiver diseaseFibrosisNon-alcoholic Fatty Liver DiseaseRisk FactorsNASH; NAFLD; EPICARDIAL FAT; CARDIAC DYSFUNCTION;Internal medicineNAFLDmedicineHumansSettore MED/12 - GastroenterologiaEjection fractionHepatologybusiness.industryFatty liverNASHHeartMiddle Agedmedicine.diseaseEndocrinologyLiverCardiovascular DiseasesEchocardiographyCardiologyFemaleSteatohepatitisbusinessPericardiumCARDIAC DYSFUNCTION
researchProduct

PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease.

2013

Background and Aim To evaluate if the presence of carotid atherosclerosis in patients with NAFLD, could be related to gene variants influencing hepatic fat accumulation and the severity of liver damage. Methods We recorded anthropometric, metabolic and histological data(Kleiner score) of 162 consecutive, biopsy-proven Sicilian NAFLD patients. Intima-media thickness(IMT), IMT thickening(IMT≥1 mm) and carotid plaques(focal thickening of >1.3 mm at the level of common carotid artery) were evaluated using ultrasonography. IL28B rs12979860 C>T, PNPLA3 rs738409 C>G, GCKR rs780094 C>T, LYPLAL1 rs12137855 C>T, and NCAN rs2228603 C>T single nucleotide polymorphisms were also assessed. The results we…

Carotid Artery DiseasesMalePathologylcsh:MedicineGastroenterology0302 clinical medicinePolymorphism (computer science)Non-alcoholic Fatty Liver DiseaseRisk FactorsGenotypeCommon carotid arterylcsh:ScienceATEROSCLEROSI0303 health sciencesMultidisciplinaryNONALCOHOLIC STEATOHEPATITISFatty liverMiddle Aged3. Good healthCarotid ArteriesCohortcardiovascular system030211 gastroenterology & hepatologyFemaleResearch ArticleAdultmedicine.medical_specialtyGenotypeSingle-nucleotide polymorphismPolymorphism Single Nucleotide03 medical and health sciencesmedicine.arteryDiabetes mellitusInternal medicinemedicineHumansClinical significancecardiovascular diseasesAllelesGenetic Association StudiesPNPLA3030304 developmental biologyAgedNAFLD PNPLA3 ATHEROSCLEROSISbusiness.industrylcsh:RMembrane ProteinsLipasemedicine.diseaseFatty Liverlcsh:Qbusiness
researchProduct